Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of Danaher Co. (NYSE:DHR). In a filing disclosed on March 27th, the Representative disclosed that they had sold between $15,001 and $50,000 in Danaher stock on February 25th. The trade occurred in the Representative’s “JP MORGAN BROKERAGE ACCOUNT” account.
Representative Robert Bresnahan, Jr. also recently made the following trade(s):
- Purchased $1,001 – $15,000 in shares of Intuit (NASDAQ:INTU) on 3/7/2025.
- Sold $1,001 – $15,000 in shares of Tesla (NASDAQ:TSLA) on 3/6/2025.
- Purchased $1,001 – $15,000 in shares of SEA (NYSE:SE) on 3/5/2025.
- Sold $1,001 – $15,000 in shares of Credo Technology Group (NASDAQ:CRDO) on 3/4/2025.
- Purchased $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 3/4/2025.
- Purchased $1,001 – $15,000 in shares of Twilio (NYSE:TWLO) on 3/4/2025.
- Sold $15,001 – $50,000 in shares of Alibaba Group (NYSE:BABA) on 3/4/2025.
- Purchased $1,001 – $15,000 in shares of Zoom Video Communications (NASDAQ:ZM) on 3/4/2025.
- Purchased $1,001 – $15,000 in shares of Intel (NASDAQ:INTC) on 3/3/2025.
- Purchased $1,001 – $15,000 in shares of Snowflake (NYSE:SNOW) on 3/3/2025.
Danaher Trading Down 2.1 %
Shares of NYSE DHR traded down $4.43 during midday trading on Friday, hitting $205.69. The stock had a trading volume of 2,388,883 shares, compared to its average volume of 3,186,485. The company has a fifty day moving average price of $214.57 and a 200 day moving average price of $236.90. The company has a market capitalization of $147.01 billion, a price-to-earnings ratio of 38.96, a PEG ratio of 2.66 and a beta of 0.82. Danaher Co. has a 1-year low of $196.80 and a 1-year high of $281.70. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31.
Danaher Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be paid a dividend of $0.32 per share. The ex-dividend date of this dividend is Friday, March 28th. This is a positive change from Danaher’s previous quarterly dividend of $0.27. This represents a $1.28 annualized dividend and a yield of 0.62%. Danaher’s dividend payout ratio is currently 24.24%.
Institutional Investors Weigh In On Danaher
Several hedge funds have recently modified their holdings of the stock. Norges Bank acquired a new position in Danaher during the fourth quarter valued at $2,130,740,000. Raymond James Financial Inc. acquired a new position in Danaher in the 4th quarter valued at approximately $391,172,000. Two Sigma Advisers LP boosted its stake in shares of Danaher by 4,248.8% during the 4th quarter. Two Sigma Advisers LP now owns 1,639,500 shares of the conglomerate’s stock valued at $376,347,000 after buying an additional 1,601,800 shares during the period. Capital World Investors increased its stake in shares of Danaher by 32.7% in the fourth quarter. Capital World Investors now owns 6,361,183 shares of the conglomerate’s stock worth $1,460,215,000 after acquiring an additional 1,566,658 shares during the last quarter. Finally, Point72 Asset Management L.P. grew its stake in Danaher by 460.6% in the fourth quarter. Point72 Asset Management L.P. now owns 1,348,544 shares of the conglomerate’s stock valued at $309,558,000 after purchasing an additional 1,107,998 shares in the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.
Insider Activity
In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 11.10% of the stock is owned by corporate insiders.
Wall Street Analysts Forecast Growth
A number of equities analysts have weighed in on the stock. Stifel Nicolaus raised shares of Danaher from a “hold” rating to a “buy” rating and set a $260.00 price objective for the company in a research report on Friday, March 14th. Jefferies Financial Group cut their target price on Danaher from $285.00 to $260.00 and set a “buy” rating on the stock in a research report on Wednesday, January 29th. Citigroup cut their price target on shares of Danaher from $285.00 to $265.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. Robert W. Baird decreased their price objective on shares of Danaher from $277.00 to $268.00 and set an “overweight” rating for the company in a report on Tuesday, January 28th. Finally, Raymond James restated a “market perform” rating on shares of Danaher in a research note on Monday, February 3rd. Five research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $278.24.
View Our Latest Stock Analysis on DHR
About Representative Bresnahan
Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania’s 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania’s 8th Congressional District. He declared candidacy for the 2026 election.
Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Recommended Stories
- Five stocks we like better than Danaher
- How Investors Can Find the Best Cheap Dividend Stocks
- MarketBeat Week in Review – 03/24 – 03/28
- What to Know About Investing in Penny Stocks
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- 4 Healthcare Stocks With Massive Gains—and More to Come
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.